ESPR Stock Summary and Trading Ideas (Esperion Therapeutics | NASDAQ:ESPR)

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Esperion Therapeutics trades on the NASDAQ stock market under the symbol ESPR.

As of June 12, 2026, ESPR stock price was flat at $3.15 with 11,198,678 million shares trading.

ESPR has a beta of 2.37, meaning it tends to be more sensitive to market movements. ESPR has a correlation of 0.08 to the broad based SPY ETF.

ESPR has a market cap of $810.83 million. This is considered a Small Cap stock.

Last quarter Esperion Therapeutics reported $80 million in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.07.

In the last 3 years, ESPR traded as high as $4.18 and as low as $.69.

The top ETF exchange traded funds that ESPR belongs to (by Net Assets): IWM, VTI, XPH, VXF, FESM.

ESPR has outperformed the market in the last year with a price return of +162.5% while the SPY ETF gained +24.1%. ESPR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.5% and +0.6%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

ESPR support price is $3.14 and resistance is $3.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ESPR shares will trade within this expected range on the day.